CURRICULUM VITAE

1.Date of Preparation May 2015

2. PERSONAL DATA:

a)NAME:

Janice Jean Phillips Dutcher

b,c)DATE AND PLACE OF BIRTH:November 10, 1950

Bend, Oregon

d)CITIZENSHIP:

USA

3.EDUCATION:

1968 - 1971BA, Honors, magna cum laude

University of Utah

1971 - 1975MD, University of California Davis

Senior Year Rotations: University of Chicago, Northwestern University, Rush Presbyterian St. Lukes Medical Center

4.POST DOCTORAL TRAINING:

1975 - 1978Medical Internship and Residency

Rush University -Presbyterian St. Lukes Hospital; Chicago, IL

1978-1981 – Medical Oncology Fellowship

Clinical Associate, Baltimore Cancer Program,

National Cancer Institute, Balitmore MD

5.MEDICAL LICENSURE AND BOARD QUALIFICATION:

a)National Board of Medical Examiners Part 1, 1973; Part 2, 1975; Part 3: July 1, 1976

Certificate: 158946 (initially licensed in Illinois)

Current Licenses: Maryland (21938); New York (152748);

DEA AD8285290

b)American Board of Internal Medicine, 1978

American Board of Internal Medicine, Subspecialty Board of Medical Oncology, 1983

6.MILITARY SERVICE:

Commissioned Officer, United States Public Health Service, 1978-1982

Inactive Reserve, 1982-

7.PROFESSIONAL ORGANIZATIONS AND SOCIETIES

Eastern Cooperative Oncology Group (member since 1983)

Study Principal Investigator, 1983-

Hematology Steering Committee, member 1983-1986

Leukemia Core Committee, member 1986-

Co-Chair, Biological Response Modifiers Committee, 1987-89

Chair, Biologic Response Modifiers Committee, 1989-1995

Bone Marrow Transplant Steering Committee, member 1993-2005

Institutional Principal Investigator, 1993-1997

Member, Scientific Advisory Committee, 1994-1995

Member, Executive Committee, 1994-1997

Member, ECOG Research & Education Foundation Executive Committee, 1995- 1998

BRM co-chair, Lymphoma Committee, 1996-2005

Member, Nominating Committee, 1996-1997

Member, Publication Committee, 2005-

Chair, Renal Subcommittee of Genitourinary Committee, 1998-2011

Member, ECOG Research & Education Foundation Executive Committee, 2010-

Member, PrECOG Data Safety and Monitoring Committee, 2014-

American Society of Clinical Oncology (ASCO) (member since 1980)

Member, Annual Meeting Program Committee, 1988; Co-Chairman, Session on AIDS and Epidemiology, 1988

Co-Chair, Session on Biologic Therapy, 1996

Member, Annual Meeting Program Committee, 1997; Co-Chair, Session on Immunotherapy and Gene Therapy, 1997

Chair and participant, Annual Meeting, Educational Session on Renal Cell Cancer, 2002

Participant, Annual Meeting, Categorical Course on Clinical Trial Design, Presentation on Phase II Trial Design, 2003.

Invited Discussant, Session on New Therapy in Renal Cell Cancer, Annual Meeting, 2004.

Invited Discussant, Session on Health Policy – FDA Drug Approval Process, ASCO Annual Meeting, 2004

Member, Annual Meeting Program Committee, 2005-2006; Track Leader, Developmental Therapeutics- Immunotherapy, 2006.

Faculty Member, Joint AACR/ASCO Workshop on Methods in Clinical Cancer Research and Protocol Development, 1996-2002; Course Program Committee, 1996; 2001

Member, Young Investigator Awards Selection Committee, 1998-2002; Chair, Awards Selection Committee, 2000-2001

Member, Program Committee and Faculty, FECS/ASCO/AACR European Clinical Methods Course - planning 1998, held June 23-29, 1999, June 24-29, 2000.

Member, Nominating Committee, 1999-2001

Member, Fellows Task Force Steering Committee, 1999-2000

Member, Task Force on Associate/Junior Active ASCO Members, 2001

Member, Maintenance of Certification Task Force, 2005-2007

Member, In-training Medical Oncology Examination Development Committee, 2009-2011

Member ASCO SEP Exam Committee, 2008 - 2011

American Association for Cancer Research (member since 1983)

Member, Subcommittee for Special Conferences, 1997-1999

Faculty, Workshop on Methods in Clinical Research, 1996-2002; Program Committee 1996; 2001

Co-Director, Special Conference on Cytokines and Cancer, Vail Colorado, Sept 20-24, 2000

American Board of Internal Medicine

Member, Medical Oncology Subspecialty Board, 1997-2003

Member, Medical Oncology SEP Update, 2002-2003

American Society of Hematology (member since 1984)

Co-Chairman, Session on Leukemia and Myeloproliferative Disorders, 1983

Member, Program Committee, 1986; Co-Chairman, Session on Transfusion Medicine, 1986.

American Association of Blood Banks (member since 1983)

Workshop Participant, Adoptive Immunotherapy, 1988-89

Session Co-Chair, Apheresis, 1992; Abstract Reviewer, 1992-1996

International Society of Hematology (member since 1986)

Co-Chairman, Session on Leukocytes, 1984

Co-Chairman, Session on Chronic Myelogenous Leukemia, 1988

American Radium Society (member since 1984)

Member, Local Arrangements Committee, 1993; Chair, Local Arrangements Committee, 1994

Moderator and Speaker, Multidisciplinary Panel on Dose Intensification, 1994

Member, Janeway Lecture Committee, 1993-1995; Chair, Janeway Lecture Committee 1996

Member, Local Arrangements Committee, 1997

Member, Public Relations Committee, 1997-1999;

Member, Executive Committee, 1997-1999

Member, Membership and Credentials Committee, 1998-1999

Member, Nominating Committee, 2001-2002

Member, Program Committee, 2004-2005

Member, Executive Committee, 2005

Member, Program Committee, 2006-2007.

Member, Nominating Committee, 2007-2009

National Leukemia Research Association

Member, Medical Advisory Board 1995 - ; Research Grant Reviewer 1995-

Israel Cancer Research Fund

Scientific Review Committee B, 1996-1998

National Kidney Cancer Association

Medical Advisory Committee, 1996 –

Volunteer Speaker at numerous patient education sessions

Session chair and speaker at annual meetings

European Society for Medical Oncology

Corresponding Member, 1997-

International Society of Biologic Therapy (member since 1989)

Program Committee, 2002-2003; Development Committee, 2003

Public Affairs Committee, 2003-2006

Board of Directors, 2001-2004

Association for Patient Oriented Research

Board member, 2011 - 2013

Additional Memberships

-American Association for the Advancement of Sciences, 1983-

-American College of Physicians, member, l978, Fellow (044202) l983-

-American Federation for Clinical Research, l982-

Chair of Session I, Eastern Division Meeting, April 2012

-American Society for Clinical Pharmacology and Therapeutics, 1984-2013

-New York Academy of Sciences, 1983-

-New York Cancer Society, Inc 1984-

-American Society for Apheresis, 1989-

-International Society for Experimental Hematology, 1993-

- Kidney Cancer Association, Scientific Adv Board, 10 yr term, continued member, 1988-

8.ACADEMIC APPOINTMENTS

1978-1981Clinical Associate

1978-1982Baltimore Cancer Research Program, Division of Cancer Treatment

National Cancer Institute, NIH

1979-1981Clinical Associate Cell Component Therapy

Baltimore Cancer Research Program, National Cancer Institute

1982

Senior Investigator, Baltimore Cancer Research Program,

National Cancer Institute

Jul 1982-Dec 1982Assistant Professor of Internal Medicine

University of Maryland Cancer Center, University of Maryland

Jan 1983-Jun 1986Assistant Professor of Medicine, Albert Einstein College of Medicine

Jul 1986-Jun 1992Associate Professor of Medicine, Albert Einstein College of Medicine

Jul 1992-1998

Professor of Medicine, Albert Einstein College of Medicine,

Bronx, New York

Oct 1998-presentProfessor of Medicine, New York Medical College

9.HOSPITAL APPOINTMENTS

Jan 1983-1997

Chief of Service, Oncology, Jack D. Weiler Hospital, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

Jan 1984-1998

Director for Apheresis Research, Blood Bank, Montefiore Medical Center

July 1986-1998Director of Immunotherapy Clinical Research Program, Montefiore

Medical Center

Jan 1993-1998

Medical Director, Bone Marrow Transplant Program, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York

Oct 1998-July 2008Associate Director for Clinical Affairs, Comprehensive Cancer Center

Our Lady of Mercy Medical Center, Bronx, New York

Oct 1998-July 2008Director of Oncology Apheresis,

Medical Director, Bone Marrow Transplant Program, Our Lady of Mercy Medical Center, Bronx, New York

July 2008-Nov 2010 Senior Attending, Cancer Center, North Division, Montefiore Medical Center, Bronx, New York

Nov 2010- Nov 2012Director of Immunotherapy Program, Division of Hematology/ Oncology

St Lukes Roosevelt Hospital Center, Continuum Cancer Centers

New York, NY

10.HONORS AND AWARDS:

-National Merit Finalist and Scholar, Scholarship Recipient, 1968

-Sterling Scholar in General Scholarship, State of Utah, 1968

Presidential Scholar from State of Utah, awarded at the White House by invitation of President Lyndon B. Johnson, 1968

-Alpha Lambda Delta, Freshman Women Honor Society, President, 1968-70

-Phi Kappa Phi, elected 1971

-Phi Beta Kappa, elected 1971

-Alpha Omega Alpha, elected 1975

-Lange Medical Publishers Award, 1975

-Finalist, Beecham Award in Hematology/Oncology for physicians in clinical research training. Southern Blood Club of American Federation of Clinical Research, Southern Meeting and Southern Society for Clinical Investigation, January, 1983

-Leukemia Society of America - Special Fellow, 1983-1985

-First Recipient of the Distinguished Alumnus Award, University of California, Davis School of Medicine, June 11, 1988.

-Recipient, First Prize for Clinical Research, Henry C. Moses Award, Montefiore Medical Center, 1989

-Recipient, Young Investigator Award, Eastern Cooperative Oncology Group, 1993

-Listed in Who's Who in Science and Engineering, 1992-

-Listed in Who's Who in America 1995-

-Listed in Who's Who in the World, 1993-

-Listed in Who's Who in the East, 1995-

-Listed in Who's Who in Medicine and Healthcare, 1997-

-Listed in Who's Who of American Women, 1997-

- Recipient of the Women of Distinction Health Care Services Award:

from the New Bronx Chamber of Commerce and the Bronx Chamber of Commerce Charitable Foundation at the second annual luncheon - Women of Distinction – in Celebration of Women’s History Month , Marina Del Rey, Bronx, NY ; also awarded proclamation from the New York City Council , March 28, 2008.

11.FELLOWSHIP AND GRANT SUPPORT

Past Support

-1982 - Pangborn Research Fund, University of Maryland $1800.

-1983-85, Leukemia Society of American Special Fellowship - $ 25,000/yr

-1983-84, National Leukemia Association Fellowship, $ 20,000

-1986-87, National Leukemia Association Award, $ 20,000

-1986-87, 5U10CA14958-S2 - ECOG supplement for IL-2/LAK cell studies in melanoma, colon cancer, and renal cell carcinoma, Co-Principal Investigator.

-1987-91, RFP/NCI-CM73702-26 - Contract for Clinical Trials of Activated Leukocytes, clinical co-principal investigator. Co-Principal Investigator,30% effort

-1986-96, NIH/NCI-P30CA1330 - Albert Einstein Cancer Center, Core Support for Cancer Research Center, clinical investigator. Program Leader, 1993-1996.

-1996-98, NIH/NCI-P30CA1130 - Albert Einstein Cancer Center, Core Support for Cancer Research, director of clinical trials and monitoring unit.

- 1986-98, 5U10CA14958 - Participation in Albert Einstein ECOG institutional grant, clinical investigator, 10% effort and funding. Principal Investigator, 1993-1997.

- 1989-90, American Association of Blood Banks National Foundation Grant -$26,000.

-1991-92, MAO/RFP NCI-CN-15339-33 - Master Agreement, Phase I Clinical and Pharmacologic Studies of new Chemopreventive Agents, Principal Investigator.

-1992-93, Institutional grant from Chiron for IL-2 based clinical and pharmacokinetic trials, $40,000

-1992-93, PI, Institutional grant from Sandoz for IL-6 based clinical and pharmacokinetic trials, $60,000

-1992-93, PI, Institutional grant from Sandoz for IL3-based Bone marrow transplantation trial, $40,000

-1993, PI, Institutional grant from Immunex for GM-CSF studies and peripheral blood stem cells, $10,000

-1993-95, PI, Institutional grant from Genetech, Inc for studies of gamma interferon in renal cell, $60,000

-1994-6, PI, unrestricted grant from Immunex for GM-CSF/IL2 study in renal cell cancer, $25,000

-1994-96, PI, Institutional grants from Chiron/Schering, for studies of IL2/IF in renal cell cancer, $50,000

-1995-96, PI, Institutional grant from Genetics Institute for phase I/II studies of IL12, $60,000

-1996-97, PI, Institutional grant from Chiron/Schering for studies of 5FU/IL2/IF in renal cell cancer, $20,000

-1997, PI, Institutional grant from Genetics Institute for Phase II study of IL12, $40,000

-1996-97. PI, Institutional grant from Ligand for studies of Targeting in renal cell cancer, $20,000.

-1997-98-PI, Institutional grant from Chiron for studies of high dose IL2 in renal cell cancer.

-1998-99, PI, RO3, Phase II study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia, $50,000/yr.

-1998-2003, PI, FDA Orphan Drug Award, Phase II Clinical and Biological Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia, $198,000/yr

-1998-2000, Co-Invest, Leukemia Society of America Transnational Research Award, Study of Biology of Arsenic Trioxide in Acute Leukemia, P Wiernik, PI, $100,000/yr

-1998-2000, PI, Institutional Grant from Immunex for Phase I/II study of CD40 Ligand in solid tumor and renal cell cancer. $ 100,000.

-2000, PI, Institutional grant from Wyeth-Ayerst for phase II study of CCI-779 in renal cell cancer, $75,000.

-2000, PI, Institutional grant from Chiron/Schering for IL2/IFN studies in renal cell cancer, $5,000.

-2000-2001, PI, Institutional grant from Bayer for Phase I trial of bayer IL2 in solid tumor, $10,000.

-2001-2004, PI, Institutional grant from Wyeth-Ayerst (CCI-779)

-2001-, PI, Institutional grant from Abgenix (ABG-EGF)

-2002-2003, PI, Institutional grant from Novartis (EPO)

-2002-2003, PI, Institutional grant from Eisai (E7070)

-2001-2007 Co-PI, Minority-Based CCOP Grant from NCI.

-2004- 2010 PI, Institutional grant from Genentech (Avastin)

-2004 –2010 PI, Institutional grant from Wylex (Vaccine)

-2004 –2009 PI, Institutional grant from Bayer (Bay 43-9006)

- 2006 –2010 PI, Institutional grant from Novartis, (IL2)

- 2007 – 2010 PI, Institutional Grant from Genentech (Avastin)

- 2010- 2012PI, Institutional Grant from Exelixis (XL184)

-2011 -2012PI, institutional grant from BMS (Anti-PD1)

- 2012 PI, institutional grant – Prometheus (Registry)

- 2011 - 2012Support of IL2 Clinical Research, ACKC philanthropic grant, $ 10,000

- 2011, 2012 LILAC – grants for equipment, freezer component, refrigerated centrifuge

12.DEPARTMENTAL AND UNIVERSITY COMMITTEES

Albert Einstein College of Medicine

Committee on Clinical Investigations, 1983-1998

Am Cancer Society Institutional Research Grant Review Committee, 1983-86

Experimental Clinical Procedures Committee, Dept of Medicine, 1984-88

Practice Plan Committee, Dept. of Medicine, 1984-1985

Departmental Research Committee, Dept of Medicine, 1986-1987

Clinical Oncology Committee, 1986-1990

Committee on Appointments & Promotions for Associate Professors, main committee 1986-1988; ad hoc committees, 1989-1991

Audio-Visual Committee, 1986-1993

Faculty Committee for the Dean's Letter, 1991-1993

Patent Committee, 1991-1992

Search Committee for Chairman of Radiation Oncology, 1992

Committee on Appointments & Promotions to Professor, main committee 1992 -1994

Associate Director for Clinical Research, Albert Einstein Cancer Center, 1993-1995

Program Leader, Hematologic Malignancies and General Oncology, Albert Einstein Cancer Center, 1993-1995

Acting Chief, Division of Oncology, 1993-1997

Hospital of Albert Einstein College of Medicine

Tissue Review Committee, 1983-1984

Quality Assurance Committee, 1984-1985

Pharmacy and Therapeutics, 1985-1995

Chair, Pharmacy and Therapeutics, 1993-1995

Transfusion Committee, 1987- 1998

Credentials Committee, 1988-1990

Chief of Service, 1984-1997

Physician's Publication Committee, 1990-1994

Medical and Executive Committee, 1991-1993

Montefiore Medical Center

MMC Division Council, 1994-1995

MMC Medical and Executive Committee, 1996-1997

Acting Chair, Dept Oncology, 1993-1997

Staff and Alumni Association Executive Committee, 1996

Institutional Review Board, 7/2006-9/2010, Consultant, 9/2010

Transfusion Committee, Montefiore North Division, 2008-2010

Medical Council, Montefiore North Division, 2009-2010

Our Lady of Mercy Medical Center

Investigational Review Committee, 1998-2008

Transfusion Committee, 1998-2008

Cancer Committee, 1999-2008, Chair, 2005-2008

New York Medical College

Member, Surgery Chair Search Committee, 2001-2002

St Luke’s Roosevelt Hospital, Continuum Cancer Centers

GU Tumor Board, 2010 -2012

Melanoma Tumor Board, 2011 –2012

Leukemia tumor Board – 2011 - 2012

13.EDUCATIONAL RESPONSIBILITIES:

1984-96, Course Co-Director, Advances in Cancer Treatment Research Symposium – 2 day course held in Manhattan, sponsored by Albert Einstein College of Medicine

1996-2002, Faculty Member, Joint AACR/ASCO Workshop on Methods in Clinical Cancer Research and Protocol Development; Course Program Committee, 1996; 2001

1998-2000, Member, Program Committee and Faculty, FECS/ASCO/AACR European Clinical Methods Course - planning 1998, held June 23-29, 1999, June 24-29, 2000.

See participation in National Meetings – ASCO, AACR, program committees and course development.

Participation in educational program of oncology dept/division throughout academic career.

14.OTHER PROFESSIONAL ACTIVITIES

a)EDITORIAL RESPONSIBILITY

Cancer Investigation, Co-editor, Controversies in Oncology, 1988-1992

Co-editor, Handbook of Oncologic and Hematologic Emergencies, Plenum Press, 1987

Your Patient and Cancer, Consultant, Queries in hematologic malignancies

Editor, Modern Transfusion Therapy, Volumes I & II CRC Press, Inc, 1990.

Editorial Board, Journal of Biologic Response Modifiers, now J Immunotherapy 1990 -1997;

Guest Editor, Intravenous Allopurinol and Tumor Lysis Syndrome, Seminars in Oncology, April 2001

Guest Editor, Interleukin-2 Therapy, Oncology, November 2002.

Section Editor, Chronic Leukemia, Current Treatment Options in Oncology, 2000-2009

Section Editor, Leukemia, Current Treatment Options in Oncology, 2010 –

Associate Editor, Medical Oncology , 1992 – 2014; Reviewer, ongoing

Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 3rd Edition, 1996.

Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 4th Edition, 2003.

Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 5th Edition, 2012

Editorial Board, J. Clinical Oncology, 1996-1998

Editorial Board, Annals of Internal Medicine, 2000 - 2003

Editorial Board, J. Clinical Pharmacology, 1997-1998; 2001-2002, 2004-2005.

Editorial Board, Kidney Cancer Journal, 2006-present

Editorial Board, J Immunotherapy, 2001-present

Editorial Board, J Clinical Oncology 2013 -

Manuscript Reviewer for:

American Journal of Medicine; Annals of Internal Medicine

Blood; Bone Marrow Transplantation

Cancer; Cancer Investigation; Cancer Research

Cancer Treatment Reports; Clinical Cancer Research

Journal of the American Medical Association

Journal of Applied Physiology

Journal of Apheresis

Journal of Biologic Response Modifiers/ now Journal of Immunotherapy

Journal of Clinical Oncology

Journal of Nuclear Medicine

Journal of the National Cancer Institute

Journal of Interferon Research

Journal of Neurologic and Neurosurgical Research

Medical Oncology

New England Journal of Medicine; Transfusion

Kidney Cancer Journal

International Journal of Immunotherapy

Annals of Oncology

b)CONSULTATIVE ACTIVITY - FEDERAL

National Cancer Institute

Member, Phase I Working Group, 1983-1998

Member, Phase II Working Group, 1983-1998

Member, IL-2/LAK Working Group, 1986-1991

Member, Study Section for Review of BRMP Task B Grants for clinical/laboratory studies of new biologic therapies, 1988, 1994.

Member, Study Section for Review of New Initiative Grants for Laboratory Correlations of Clinical Trials, NCI, March 1990.

Member, Site Visit Team, Program Project Grant in Acute Leukemia, 1991

Member, Site Visit Team, Program Project Grant in Chronic Myelogenous Leukemia, 1994

PDQ External Advisory Board, protocol reviewer, 1994- 1998

Member, Site Visit Teams, Cancer Center Reviews, 1994, 1997, 1998

Member, Subcommittee D, Research Programs Review Committee, 1994 -1998

Member, Informed Consent Working Group, 1995-1998

Member, Subcommittee A, Cancer Centers Review Committee, 1998-2002

Member, NCI Central IRB, 1999-2001

Member and Section Leader, PRG Report on Kidney and Bladder Cancer, 2001-2002

Ad Hoc member, Cancer Biomarker Study Section, Oct 2007, February 2008.

Ad Hoc Member, Cancer Immune Therapy Study Section, March 2008.

Member, Cancer Biomarker Study Section, 2008-2012

Ad Hoc member, Cancer Biomarker Study Section, 2012 –

Member, GU Steering Committee, 2008-2012

Member, Renal Cancer Task Force, 2010 -

Med Onc Co-Chair, Renal Cancer Task Force, 2015-

National Heart, Lung and Blood Institute

Member, Data Safety and Monitoring Committee for the

Trial to reduce Alloimmunization to Platelets

(TRAP study), 1990-1995

Member, Site Visit Team, National Marrow Donor Program, 1994

Member, Ad Hoc panel to review T-cell Depletion Trial in Bone Marrow Transplant from Unrelated Donors, 1995

National Institutes of Health

Panel Member, Consensus Development Conference, Early Melanoma, Diagnosis and Management, January 27-29, 1992

Member, National Bone Marrow Donor Registry Advisory Committee of the National Institutes of Health, appointed by Secretary Louis B. Sullivan, M.D., 1993

Food and Drug Administration

Observer, Oncology Drug Advisory Committee, January 1995-July 1995

Member, Oncology Drug Advisory Committee, July 1995-1999

Chair, Oncology Drug Advisory Committee, July 1996-1999

Ad Hoc Consultant, 1999-present

CONSULTATIVE ACTIVITY – PRIVATE

Member, Data Safety and Monitoring Committee, Sanolfi, Oxaliplatin Colorectal phase III studies, 2000-2002.

Pfizer Visiting Professorship in Oncology, Academic Advisory Board. 2007-2010; Chair, 2009-2010.

Member, Scientific Advisory Board, Univ Pittsburgh Cancer Institute, 1998-2010

Chair, Data Safety and Monitoring Committee, TRIST – Oxford Biomedica - TROVAX phase III clinical trial, 2007-2010.

Member, Medical Advisory Board, Meniscus Medical Education Ltd, 2006- 2010

Member, Data Safety and Monitoring Committee, Medarex/BMS, Ipilimumab, multiple clinical trials, 2005-present

Speaker’s Bureau: Pfizer, Novartis, Prometheus, GSK

Consultant, Prometheus Labs, 2012-present

Member, Data Safety and Monitoring Committee, Merck, Anti-PD1, 2013-2015 acknowledged on manuscript – Pembrolizumab in Ipilimumab-refractory melanoma.2015

Member, Data Safety and Monitoring Committee, Tracon, 2014-present

Member, Data Safety and Monitoring Committee, PrECOG, 2014-present

Chair, Data Safety and Monitoring Committee, BMS, Nivolumab randomized adjuvant trial, 2015-

PHILANTHROPIC LEADERSHIP

Associate Director, Cancer Research Foundation, 1998-present

RESEARCH PROTOCOLS:

-Co-Chairman, Phase III Study of Mitoxantrone and Cytosine Arabinoside versus Daunorubicin and Cytosine Arabinoside in Acute Non-Lymphocytic Leukemia, 1983-1986

-Co-Chairman, Phase III Study of Mitoxantrone and Cytosine Arabinoside in relapsed ANLL or Blast Crisis of CML, 1983-1985

-Co-Chairman, Low-dose Cytosine Arabinoside in elderly patients with leukemia, 1983-1986

-Co-Chairman, Phase II Study of Deoxydoxorubicin in refractory acute leukemia, with pharmacology, 1983-1987

-Co-Chairman, Phase II study of Homoharringtonine in refractory acute leukemia, with pharmacology, 1983-1986

-Co-Chairman, Phase III Study of MOAD in adult acute lymphocytic leukemia, 1983-1989

-Chairman, Phase III study of autologous frozen platelet transfusion in alloimmunized patients with acute non-lymphocytic leukemia, 1984-

-Chairman, Indium-111-labeled granulocyte migration in infected neutropenic patients, 1983-1991

-Chairman, Ethiodized Oil Emulsion in the identification of hepatic and splenic metastases, 1983-1989

-Co-Chairman, institutional Phase III study of Idarubicin and Cytosine Arabinoside versus Daunorubicin and Cytosine Arabinoside in ANLL, 1986-1988

-Co-Chairman, Phase II study of mitoxantrone and 5-azacytadine in chronic myelogenous leukemia, blast crisis. (EST 5484).

-Co-Principal Investigator, Phase II study of Interleukin-2 and Activated Autologous Leukocytes in Patients with Untreatable Malignancy, 1986-1989.

-Co-Chairman, Indium-111-labeled LAK cells and platelets in patients treated with interleukin-2, 1987-1989.

-Co-Chairman, ancillary clinical studies in patients treated with interleukin-2

-Chairman, Phase I study of menogaril in relapsed/refractory acute leukemia with pharmacology.

-Co-Chairman, Phase II study of mitoxantrone, CCNU, vinblastine in relapsed Hodgkin's disease. (EST PH484).

-Chairman, Phase II study of menogaril in acute leukemia (EST 8490)

-Chairman, Phase II studies of interleukin-2 alone and with alpha interferon in patients with renal cell and melanoma, 1990-92.

-Chairman, phase I-II studies of interleukin-6 in patients with advanced malignancy, 1992-1994

-Chairman, Phase II study of carboplatin in blast crisis of chronic myelogenous leukemia (EST 1992)

-Principal Investigator, Master Agreement for Phase I Clinical and Pharmacological Studies of Chemopreventive Agents 1990-92.

-Chairman, Phase II study of all-trans retinoic acid in chronic myelogenous leukemia (E1993) 1994-97

-Co-Chairman, Phase II study of IL-4 in CLL and non-Hodgkins lymphoma (E5Y92), 1995-1998

-Co-Chair, Phase II study of Arsenic Trioxide in relapsed/refractory acute leukemia and blast crisis of CML, and myelodysplasia (funded by NCI-RO3 and FDA Orphan Grant) 1998-2002

- Co-Chair, Phase II study of Arsenic Trioxide plus Ascorbic Acid in relapsed/refractory acute leukemia and blast crisis of CML, and myelodysplasia (funded by FDA Orphan Grant) 2002-

-Institutional Chair, Phase III study of high dose IL2 versus outpatient subcutaneous IL2 plus interferon in metastatic renal cell cancer. 1998-2000

-Institutional Chair, Phase II study of peptide vaccine plus IL2 in metastatic melanoma. 1998-

-Chair, Phase III study of adjuvant high dose IL2 versus observation in high risk, resected renal cell cancer, 1998-2002

-Institutional Chair, Phase I and Phase II studies of CD40 Ligand. Phase II in renal cell cancer, 1998-2001

- Institutional Chair, Phase I study of IL2 plus DENSPM. 2000.

-Institutional Chair, Phase II study of CCI-779 for renal cell cancer. 2000-2001

-Institutional Chair, Phase I study of CCI-779 plus Interferon for RCC, 2002-2004

-Institutional Chair, Phase I trial of Bayer IL2, 2000-2002

-Institutional Chair, Phase I trial of PEG interferon plus IL2 in renal cell cancer, 2000-2003

-Institutional Chair, Phase II trial of ABX-EGF in metastatic RCC, 2001-2004

-Institutional Chair, Phase II trial of Epothilone 906 in metastatic RCC, 2002.

-Institutional Chair, Phase II trial of E7070 in metastatic RCC, 2002-2003

-Chair, Pilot study of Adriamycin plus Gemcitabine in sarcomatoid RCC, 2001-2003

-Institutional Chair, Phase II trial of IFN plus genesense (anti-bcl 2) in RCC, 2003-2005

-PI, Multicenter trial of IL2 plus thalidomide in RCC 2003-2006

-Institutional Chair, Randomized Phase II trial of Avastin +/- Tarceva in RCC, 2004

-Institutional Chair, Randomized Phase II trial of Bay 43-9006 vs placebo in RCC, 2004-2005

-Institutional Chair, Adjuvant g250 Mab vs placebo following nephrectomy in RCC, 2004-

· Institutional Chair, Phase II trial of temodar + thalidomide in melanoma, 2003-2004

· Institutional Chair, Phase III trial of SU11248 vs IFN in RCC, 2005-2007

· Institutional Chair, Phase II trial of IMOxine in RCC, 2005-2007

· Institutional Chair, Phase II open label trial of SU11248 in GIST, 2005-2007

· Institutional Chair, Phase II trial of Sutent +/- Avastin in RCC, 2007-2008.

· Institutional Chair, Phase II trial of Axitinib following Sorafenib, 2007-2008.

· Institutional Chair, Phase II trial of Axitinib vs Sorafenib following Sunitinib, 2008-2009.

· Institutional Chair, Phase II trial of Temsirolimus vs Sorafenib, following sunitinib, 2008-2010.

· Institutional Chair, Phase I of XL184 drug-drug interaction study in renal cell cancer 2010-2012

· Institutional Chair, Phase II dose-finding study of Anti-PD-1 antibody in renal cell cancer, 2011-2012

HOME/WORK ADDRESS

750 Kappock Street, Apt 511

Riverdale, New York 10463

Email: jpd4401@ aol.com

15.PUBLICATIONS

A)Original Peer Reviewed Articles

1. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Alloimmunization following platelet transfusion: The absence of a dose-response relationship. Blood 1981; 57; 395-398.

2. Dutcher JP, Schiffer CA, Johnston GS: Rapid migration of Indium-111-labelled granulocytes to sites of infection. N Engl J Med 1981; 304; 586-589.

3. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long-term follow-up of patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 1981; 58; 1007-1011.

4. Schiffer CA, Dutcher JP, Hogge DE, Aisner J: Histocompatible platelet transfusion for patients with leukemia. Plasma Therapy and Transfusion Technology 1982; 3; 272-28l.

5. Schiffer CA, Aisner J. Dutcher JP: Platelet cryopreservation using dimethylsulfoxide. Annals N Y Academy of Science 1983; 411; 161-169.

6. Hogge DE, Dutcher JP, Aisner J, Schiffer CA: Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Amer J Hematol 1983; 14; 363-369.

7. Mirvis S, Dutcher JP, Haney PJ, Whitley NO, Aisner J: Serial CT of malignant pleural mesothelioma. Am J Radiology 1983; 140; 665-670.

8. Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH: Potential HLA matched platelet donor availability for alloimmunized patients. Transfusion 1983; 23; 286-289.

9. Wiernik PH, Riggs C Jr, Dutcher JP: Adriamycin or Daunorubicin in combination with cytosine arabinoside for the treatment of acute nonlymphocytic leukemia. Drugs Exper Clin Res 1983; 9; 403-406.

10. Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Aisner J, Wiernik PH. Alloimmunization prevents the migration of transfused Indium-111-labeled granulocytes to sites of infection. Blood 1983; 62; 354-360.

11. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62; 815-820.

12. Schiffer CA, Aisner J, Dutcher JP, Wiernik PH: Sustained post-transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J Hematol 1983; 15; 65-74.

13. Dutcher JP, Haney PJ, Whitley NO, Finley R, Pearl P, Didolkar MS, Wiernik PH: Ethiodized oil emulsion 13 in computed tomography of hepatoma. J Clin Oncol 1984; 2; 118-123.

14. Hogge DE, Dutcher JP, Aisner J, Schiffer CA: The ineffectiveness of random donor platelet transfusion in splenectomized alloimmunized recipients. Blood 1984; 64; 253-256.

15. Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D: High dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64; 937-940.

16. Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of thrombocytopenia and bleeding among patients with solid tumors. Cancer 1984; 53; 557-562.

17. Dutcher JP: Decreased sensitivity of early imaging with In-111 oxine-labeled leukocytes in detection of occult infection. J Nuc Med 1984; 25; 1150-1151. (letter to editor).

18. Paietta E, Dutcher JP, Wiernik PH: Terminal transferase positive acute promyelocytic leukemia: In vitro differentiation of a T-lymphocytic/promyelocytic hybrid phenotype. Blood 1985; 65; 107-114..

19. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47; 2486-2493.

20. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clinical Oncology 1987; 5; 1232-1239.

21. Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin-2 and lymphokine-activated killer cells. Cancer Research 1987; 47; 4208-4212.

22. Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF: Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987; 1; 565-567.

23. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration and survival. J Clin Oncol 1987; 5; 1364-1372.

24. Lipton RB, Galer BS, Dutcher JP, Portenoy RK, Berger A, Arezzo JC, Mizruchi M, Wiernik PH, Schaumburg HH: Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer. Arch Neurol 1987; 44; 944-946.

25. Wadler S, Einzig AI, Dutcher JP, Ciobanu N, Laudau L, Wiernik PH: Phase II trial of recombinant alpha-2b-interferon and low dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am J Clin Oncol 1988; 11; 55-59.

26. Dutcher JP, Wiernik PH, Markus S, Weinberg V, Schiffer CA, Harwood KV: Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: An eight year follow-up. Leukemia 1988; 2; 413-419.

27. Dutcher JP, Wadler S, Wiernik PH: Biological response modifiers in gynecologic malignancies. Yale Journal of Biology and Medicine 1988; 61; 367-378.

28. Dutcher JP, Wiernik PH: Extension of remission in acute non-lymphocytic leukemia. (letter to the editor) J Clin Oncol 1988; 6; 1783-1784.

29. Dutcher JP, Riggs CE, Strauman JJ, Link B, Wiernik PH: A phase I-II trial of 4'deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia. Clinical Pharmacology and Therapeutics 1989; 45; 424-430.

30. Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M: A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7; 477-485.

31. Margolin K, Rayner AA, Hawkins M, Atkins M, Dutcher JP, Fisher RI, Weiss GR, Doroshow J, Jaffe H, Roper MA, Parkinson D, Wiernik P, Creekmore SP, Boldt DH. Toxicity of interleukin-2 and lymphokine-activated killer (LAK) cell therapy. J Clin Oncol 1989; 7; 486-498.

32. Walewski J, Paietta E, Dutcher J, Wiernik PH: Evaluation of in-vivo natural killer and lymphokine-activated killer (LAK) cell activity in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. J Cancer Res Clin Oncol 1989; 115; 170-174.

33. Lipton RB, Apfel S, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik PH, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39; 368-373.

34. Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH: Granulocyte transfusion therapy and amphotericin B - Adverse reactions? Am J Hematol 1989; 31; 102-108.

35. Paietta E, Gucalp R, Papenhausen P, Dutcher JP, Wiernik PH: TDT+/non-lymphoid antigen+ acute leukemias: Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell. Leukemia 1989; 3; 485-491.

36. Baker H, Marcus SL, Frank O, Petrylak DP, DeAngelis BA, Dutcher JP, Wiernik PH: Interleukin-2 enhances biopterins and catecholamine production during adoptive immunotherapy for various cancers. Cancer 1989; 64; 1226-1231.

37. Dutcher JP, Riggs C, Fox JJ, Johnston GS, Norris D, Wiernik PH, Schiffer CA: The effect of histocompatibility factors on pulmonary retention of Indium-111-labeled granulocytes. Am J Hematol 1990; 33; 238-243.

38. Wiernik PH, Schwartz B, Dutcher JP, Turman N, Adinolfi C: Successful treatment of hairy cell leukemia with beta-ser interferon. Am J Hematol 1990; 33; 244-248.

39. Weisfuse IB, Graham DJ, Will M, Parkinson D, Snydman DR, Atkins M, Karron RA, Feinstone S, Rayner AA, Fisher RI, Mills BJ, Dutcher JP, Weiss GR, Glover A, Kuritsky JN, Hadler SC. An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine activated killer cells. J Infect Dis 1990; 161; 647-652.

40. Dutcher JP, Salva KM, Wiernik PH: Successful treatment of hairy cell leukemia with 2'-deoxycoformycin after failure of interferons alpha or beta. Am J Clin Oncol 1990; 13; 290-293.

41. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH: Acute renal failure during interleukin-2 treatment - Evidence for an intrinsic renal lesion. J Clin Oncol 1990; 8; 1839-1846.

42. Dutcher JP, Marcus SL, Tanowitz HB, Wittner M, Fuks JZ, Wiernik PH: Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with the acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer 1990; 66; 2417-2420.

43. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, Atkins MB, Hawkins MJ: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990; 8; 1650-1656.

44. Sznol M, Mier JW, Sparano J, Gaynor E, Weiss GR, Margolin K, Bar MH, Hawkins MJ, Atkins M, Dutcher JP, Fisher RI, Boldt DH, Doroshow JH, Louie A, Aronson FR: A phase I study of high dose interleukin-2 in combination with interferon-alfa 2B. J Biol Response Modifiers 1990; 9; 529-537.

45. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ: A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9; 59-64.

46. Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, Margolin K, Aronson FR, Hawkins M, Atkins M. A phase II study of high dose continuous infusion interleukin-2 with lymphokine activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991; 9; 641-648.

47. Sklarin NT, Dutcher JP, Wiernik PH: Lymphomas following cardiac transplantation. Am J Hematol 1991; 37; 105-111.

48. Wiernik PH, Dutcher JP, Paietta E, Hittelman WN, Vyas R, Strack M, Castaigne S, Degos L, Gallagher RE: Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid. Leukemia 1991; 5; 504-509.

49. Gucalp R, Paietta E, Weinberg V, Papenhausen P, Dutcher JP Wiernik PH: Terminal transferase expression in acute myeloid leukemia: Biology and prognosis. Br J Haematology 1991; 77; 48-54.

50. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, Grima K, Wiernik PH, Brandt LJ. Colonic ischemia complicating immunotherapy with interleukin-2 and alpha-interferon. Cancer 1991; 68; 1538-1544.

51. Lipton RB, Galer BS, Dutcher JP, Portnoy RK, Pahmer V, Meller F, Arezzo JC, Wiernik PH: Large and small fiber type sensory dysfunction is prevalent in patients with cancer. J Neurol Neurosurg Psychiatry 1991; 54; 706-709.

52. Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H: Hypovitaminosis C in patients treated with high-dose interleukin-2 and lymphokine-activated killer cells. Am J Clinical Nutrition 1991; 54 (suppl); 1292S-1297S.

53. Moskowitz C, Dutcher JP, Wiernik PH: Association of thyroid disease with acute leukemia. Am J Hematol 1992; 39; 102-107.

54. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Demchak PA, Gucalp R, Fisher RI, Clark GM: A randomized phase II trial of continuous infusion interleukin 2 or bolus injection interleukin 2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10; 275-281.

55. Wiernik PH, Dutcher JP: Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 1992; 6 (Suppl 1); 67-69.

56. Dutcher JP Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, Cassileth PA: Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6; 770-775.

57. Baker H, Marcus LS, Frank O, Petrylak DP, DeAngelis B, Baker ER, Dutcher JP, Wiernik PH: Effect of interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers. J Am Coll Nutr 1992; 11; 482-486.

58. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, Wiernik PH: Survival after phase II treatment of advanced renal cell carcinoma with taxol or high dose interleukin-2. J Immunotherapy 1993; 13; 275-281.

59. Sparano JA, Wiernik PH, Leaf A, Dutcher JP: Infusional cyclophosphamide, doxorubicin and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11; 1071-1089.

60. Mazurek C, Dutcher JP, Schwartz EL, Garl S, Benson L, Wiernik PH: Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia. Invest New Drugs 1994; 11; 313-322.

61. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan R, Raschko J, Somlo G, Dutcher J, Hawkswoth K, Yonemoto L, Caliendo G, Cavasotto G: Phase I trial of interleukin-2 plus doxorubicin. J Immunotherapy 1993; 14; 70-76.

62. Sparano JA, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP: Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha2B in patients with advanced breast cancer. Cancer Res 1993; 53; 3509-3512.

63. Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L: Long term followup of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A Non-anthracycline containing regimen. Leukemia 1993; 7; 1236-1241.

64. Sparano JA, Micetich KC, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Aronson FR, Rubinstein LV, Mier JW: Randomized phase III trial of treatment with high dose interleukin-2 either alone or in combination with interferon-alpha2A in patients with advanced melanoma. J Clin Oncol 1993; 11; 1969-1977.

65. Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, Gaynor ER, Boldt DH, Doroshow JH, Aronson FR: A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunotherapy 1994; 15; 74-78.

66. Oleksowicz L, Zuckerman D, Puszkin E, Dutcher JP: Effects of interleukin-2 administration on platelet function in cancer patients. Am J Hematol 1994; 45; 224-231.

67. Vlock DR, Snyderman C, Johnson J, Myers E, Rubin J, Dutcher J, Adams G: Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group. J Immunotherapy 1994; 15; 134-139.

68. Margolin K, Aronson F, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Stewart M, Doroshow JH, Ernest ML, Mier JW, Dutcher JP, Gaynor ER, Weiss GR. Phase II studies of recombinant human IL-4 in advanced renal cancer and malignant melanoma. J Immunotherapy 1994; 15; 147-153..

69. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Sarta C, Carney D, Elkind R, Shah M, Valentine ES, Dutcher JP: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A followup report of a highly active regimen. Leukemia and Lymphoma 1994; 14; 263-271.

70. Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L: Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematology 1994; 47; 41-44.

71. Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E: Platelet activation induced by interleukin-6: Evidence for a thromboxane sensitive mechanism. Thrombosis and Haemostasis 1994; 72; 302-308..

72. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Ernest ML, Sznol M, Mier JW: Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, pancreas and other tumors. J Immunotherapy 1994; 16; 216-223.

73. Sagayadan GE, Wiernik PH, Sun N, Ahern G, Thompson D, Hallam S, Hu XP, Dutcher JP, Gallagher RE: Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myelogenous leukemia: Increased inhibition by all-trans and 13-cis retinoic acids in advanced stage disease. Leukemia Res 1994; 18; 741-748.

74. Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, Wiernik PH: Short Report: A distinct coagulopathy associated with interleukin-2 therapy. Br J Haematology 1994; 88; 892-894.

75. Oleksowicz L, Mrowiec Z, Issacs R, Dutcher JP, Puszkin E: Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation. Am J Hematology 1995; 48; 92-99.

76. Mrowiec ZR, Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Lalezari P, Puszkin EG: A novel technique for preparing improved buffy coat platelet concentrates. Blood Cells, Molecules and Diseases 1995; 21; 25-33.

77. Khalil A, Ciobanu N, Sparano JA, Gucalp R, Dutcher JP, Wiernik PH: Pilot study of high dose mitoxantrone and busulfan plus autologous bone marrow transplantation in patients with advanced malignancies. Bone Marrow Transplantation 1995; 15; 93-97.

78. Bennett RT, Lerner SE, Taub HC, Caliendo G, Dutcher JP, Fleischman J: Cytoreductive surgery for stage IV renal cell carcinoma. J Urology 1995; 154; 32-34..

79. Weiss GR, Margolin KA, Sznol M, Atkins MB, Oleksowicz L, Isaacs R, Sosman JA, Doroshow JH, Trehu EG, Dutcher JP, Fisher RI: A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunotherapy 1995; 18; 52-56.

80. Oleksowicz L, Dutcher JP: Adhesive receptors expressed by tumor cells and platelets: Novel targets for therapeutic anti-metastatic strategies. Medical Oncology 1995; 12; 95-102.

81. Dutcher JP, Leong T, Makary AZ, Bennett J, Frontiera M, Miller H, Wiernik PH: A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: A Study of the Eastern Cooperative Oncology Group. Leukemia 1995; 9; 1638-1642.

82. Paietta E, Nelson DL, Andersen J, Dutcher JP, Wiernik PH: Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Medical Oncology 1995; 12; 121-124.

83. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E: Characterization of tumor-induced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thrombosis Research 1995; 79; 261-264.

84. Mrowiec ZR, Oleksowicz L, Zuckerman D, DeLeon-Fernandez M, Khorshidi M, Dutcher JP, Puszkin EG: Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: Combined strategies for reducing platelet activation during storage. Transfusion 1996; 36; 5-10.

85. O'Boyle KP, Colletti D, Mazurek C, Wang Y, Ray SK, Diamond B, Rosenblum MG, Epstein AL, Shochat D, Dutcher JP, Wiernik PH, Klein RS: Potentiation of antiproliferative effects of monoclonal antibody Lym-1-gelonin on human Burkitt's lymphoma cells with gamma interferon and tumor necrosis factor. J Immunotherapy 1996; 18; 221-230.

86. Oleksowicz L, Puszkin E, Mrowiec Z, Isaacs R, Dutcher JP: Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. Cancer Investigation 1996; 14; 307-316.

87. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP: Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J. Clinical Oncology 1996; 14; 3026-3035.

88. Sparano JA, Lipsitz S, Wadler S, Hansen R, Bushunow PW, Kirkwood J, Flynn PJ, Dutcher JP, Benson AB: Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-( in patients with advanced pancreatic cancer. ECOG Protocol 3292. Am J. Clin Oncol 1996; 19; 546-551.

89. Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH: Concurrent phase I trials of intravenous interleukin-6 in solid tumor patients: Reversible dose-limiting neurologic toxicity. Cancer Clin Res 1997; 3; 39-46.

90. Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Paietta E, Etkind P: Human breast carcinoma cells synthesize a protein immunorelated to platelet GPIb with different functional properties. J Lab Clin Med 1997; 129; 337-346.

91. Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins MB: Outpatient subcutaneous interleukin-2 and alpha interferon for metastatic renal cell cancer: Five year follow-up of the cytokine working group study. The Cancer Journal from Scientific American 1997; 3; 157-162.

92. Dutcher JP, Coletti D, Paietta E, Wiernik PH: A pilot study of alpha interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leukemia Res 1997; 21; 375-380.

93. O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, Wiernik PH, Horwitz SB: Development of two radioimmunoassays to detect taxol in sera and in cerebrospinal, ascitic, and pleural fluids from patients. Cancer 1997; 79; 1022-1030..

94. Leaf AN, Neuberg D, Schwartz EL, Wadler S, Ritch PS, Dutcher JP, Adams GL: An ECOG phase II study of Amonifide in unresectable or recurrent carcinoma of the head and neck (PB390). Invest New Drugs 1997; 15; 165-172.

95. Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Etkind P: A GPIb -related protein is expressed by fresh human breast carcinoma tissue and is regulated by a PKC-sensitive mechanism. Experimental Cell Research 1997; 237; 110-117.

96. Malik UR, Dutcher JP, Caliendo G, LaSala P, Mitnick R, Wiernik PH. Phase II trial of merbarone in patients with malignant brain tumors. Medical Oncology 1997; 14; 159-162.

97. Mrowiec ZR, Oleksowicz L, DeLeon-Fernandez M, Puszkin EG, Dutcher JP: Apyrase, ascorbic acid and aprotinin ameliorate the storage lesion in pelleted platelet preparations. Biotechnic & Histochemistry 1997; 72; 259-267.

98. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J, for the Cytokine Working Group: Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group Experience, 1989-1997. Cancer Journal of Scientific American 1997; 3(Suppl 1); S73-S78.

99. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose IL-12 exposure on IL-12-associated toxicity and IFN-gamma production. Blood 1997; 90; 2541-2548.

100. Schiller JH, Neuberg D, Burns D, Ritch P, Larson M, Levitt M, Dutcher JP: An Eastern Cooperative Oncology Group phase I trial of all-trans retinoic acid and interferon-alpha: E2Y92. Investigational New Drugs 1997; 15; 319-324.

101. Wu JJ, Caliendo G, Hu X-P, Dutcher JP: Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Medical Oncology 1998; 15; 44-49.

102. Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH: Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998; 12; 1037-1040.

103. Wiernik PH, Dutcher JP, Einzig AI, Sparano J, Frank M, Friedenberg W: Mitoxantrone, vinblastine and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor prognosis Hodgkin's disease. Cancer Journal for Scientific American 1998; 4(July/Aug); 254-260.

104. Wadler S, Atkins M, Haynes H, Karp D, Neuberg D, Dutcher JP: Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon-( -2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group study PZ991. Cancer Journal for Scientific American 1998; 4(July/Aug); 261-268.

105. Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuckter L, Weiner LM, Dutcher JP: Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha interferon. Medical Oncology 1998; 15; 191-198.

106. AML Collaborative Group: A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematology 1998; 103; 100-109.

107. Oleksowicz L, Dutcher JP: A phase II pilot trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma. J. Cancer Research and Clinical Oncology, 1999; 215; 101-108.

108. Atkins MB, Lotze MT, Dutcher JP, Fisher R, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin-2 therapy for metastatic melanoma: Analysis of 270 patients treated between 1985-1993. J Clin Oncol 1999; 17; 2105-2116.

109. Moadel A, Morgan C, Fatone A, Grennan J, Carter J, LaRuffa G, Skummy A, Dutcher JP: Seeking meaning and hope: Self-reported spiritual and existential needs among an ethnically-diverse cancer patient population. Psycho-Oncology 1999; 8; 378-385.

110. Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt AJ: Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: Results of ECOG Study E5282. Medical Oncology 1999; 16; 261-266.

111. Dutcher JP. Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M: Phase II trial of interleukin-2, interferon-alpha and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study. Cancer Clinical Research 2000; 6; 3442-3450.

112. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S: Torsade de Pointes in three leukemia patients treated with arsenic trioxide. Blood 2001; 97; 1514-1516.

113. Vonderheide RH, Dutcher JP, Eckhardt G, Anderson JE, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG: Phase I study of recombinant human CD40 ligand (rhuCD40L) (AVREND) in cancer patients. J Clin Oncology 2001; 19; 3280-3287.

114. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Wiernik PH, Chiaramida S: Monitoring the cardiac toxicity with arsenic trioxide (letter to editor). Blood 2001; 98; 1633-1634.

115. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferone alfa-2b in patients with metastatic melanoma: Results of two phase II Cytokine Working Group trials. J Clin Oncol 2001; 19; 3194-3202.

116. Vonderheide RH, Dutcher JP, Anderson JE, Caron DA, Gribben JG: CD40 Ligand therapy of lymphoma patients. (Letter to Editor response) J Clin Oncol 2001; 19; 4351-4353.

117. Margolin K, Atkins MB, Thompson JA, Ernstoff MS, Weber J, Flaherty L, Clark JJ, Weiss G, Sosman J, Smith JA, Dutcher JP, Gollob J, Longmate J, Johnson D: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002; 128; 214-218. (Online - DOI 10.1007/s00432-002-0323-8) (Springer-Verlag)

118. Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ: A phase II study of 13-cis-retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: An Eastern Cooperative Oncology Group Study (E3893). Cancer Invest 2003; 21(1); 41-46.

119. Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RC, Dutcher JP, Wiernik PH, Oken MM: Eastern Cooperative Group Study. Phase II study of alpha 2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): A trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98; 100-109.

120. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME: Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003; 63; 6069-6075.

121. King M-C, Marks JH, Mandell JB, for the New York Breast Cancer Study Group (including Ben-Yishay M, Dutcher HP, Gross SJ, Runowicz CD, Venkataraj U, at Albert Einstein College of Medicine/Montefiore Medical Center): Breast and ovarian cancer risks due to inderited mutations in BRCA1 and BRCA2. Science 2003; 302; 643-645.

122. Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ: Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Medical Oncology 2003; 20; 271-281.

123. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA: Adjuvant high dose bolus interleukin-2 for patients with high-risk renal cell carcinoma – A Cytokine Working Group Randomized Trial. J Clin Oncol 2003; 21; 3133-3140.

124. Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK, Benson III AB, Eastern Cooperative Oncology Group: Phase II study of interferon gamma in malignant carcinoid tumors (E9292): A trial of the Eastern Cooperative Oncology Group. Invest New Drugs 2004; 22; 75-81.

125. Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R, Wiernik PH: Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematology 2004; 124; 610-617.

126. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose-levels of CCI-779, a novel mTOR kinase inhibitor in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22; 909-918.

127. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollup J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiant Oncol Biol Phys 2004; 48; 984-990.

128. Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer-IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004; 60; 1-17.

129. Adiga GU, Dutcher JP, Larkin M, Garl S, Koo J: Characterization of bone metastases in patients with renal cell cancer. Br J Urology, 2004; 93; 1237-1240.

130. Rowinsky EK, Schwartz G, Gollob J, Thompson J, Vogelzang N, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Roskos L, Foon KA, Schwab G, Dutcher JP: Safety, pharmacokinetics and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody, in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22; 909-918.

131. Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP: Idarubicin and standard dose cytosine arabinoside in relapsed and refractory adult acute lymphocytic leukemia (ALL). Cancer 2004; 101; 1414-1419.

132. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell cancer. Cancer 2004; 101(7); 1545-1551.

133. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan T, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollop JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1); 133-141.

134. Dutcher JP, Lee S, Makary AZ, Londer H, Farnen JP, Bennett JM, Paietta E, Gallagher RE, Rowe JM, Goloubeva O, Wiernik PH: Phase II study of all-trans retinoic acid (ATRA) in accelerated phase or early blastic phase of chronic myeloid leukemia: A Study of the Eastern Cooperative Oncology Group (E1993). Leukemia/Lymphoma 2005; 46 (3); 377-385.

135. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ: Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Research 2005; 11(3); 1181-1189.

136. Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G: Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy, E4896, an Eastern Cooperative Group Study. Cancer 2005; 104; 2392-2399.

137. Koulova L, Novik Y, Caliendo G, Wiernik PH, Dutcher JP: A phase II study of moderate dose IL2 and GM-CSF in patients with metastatic or unresectable renal cell carcinoma. J Immunotherapy 2005; 28; 576-581.

138. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP: The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 41 (18): 2935-2945.

139.

O’Boyle KP, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaleya R, Steinberg JJ, Dutcher JP, Wiernik PH: Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn. Cancer Immun 2006; 6; 5-9.

140.Kunthur A, Wiernik PH, Dutcher JP: Renal parenchymal tumors and lymphoma in the same patient: A case series and review of literature. Am J Hematol 2006; 81; 271-280.

141.Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Future Phase II Clinical Trials Design: Methods in Translational Research from the Eastern Cooperative Oncology Group. Clinical Cancer Research, 2006; 12; 1966-1969.

142.Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU (MVC): Long-term follow-up of patients treated with advanced and poor-prognosis Hodgkin’s disease. Leukemia and Lymphoma 2006; 47; 641-656.

143.Moadel AB, Morgan C, Dutcher JP: Psychosocial needs assessment among an underserved, ethnically diverse cancer patient population. Cancer 2007; 109; 446-454.

144.Hudes G, Carducci M, Tomczak P, Dutcher JP, Figlin R, Kapoor A, Staroslawska E, Sosman J, Atkins M, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, Galand L, Thiele A, O’Toole T, Kong S, Park Y, Moore L, Motzer R. Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med 2007; 356; 2271-2281.

145.Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM: Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunotherapy 2007; 30; 455-467.

146.Margolin KA, Synold TW, Lara P, Frankel P, Lacey SF, Quinn D, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR: Oblimersen and Alpha Interferon in metastatic renal cancer: A Phase II study of the California Cancer Consortium. J Cancer Res and Clin Oncol 2007; 133; 705-711.

147.Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, FlahertyLE, Baar J, Sosman J, Weber J, Lathia C, Smith J, Schwartz B, Cihon F: Phase I trial of Bay 50-4798, an IL-2-Specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007; 13; 3312-3319.

148.Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O’Toole T, Boni JP, Dutcher JP: Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma: J Clin Oncol, 2007; 25(25); 3958-3964.

149.Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP, Ghavamian R: Renal medullary carcinoma: The Bronx experience. Urology 2007; 70; 878-882.

150.Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin H, Dutcher JP, Ryba S, Xia Q, Scappaticci FA, McDermott D: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cancer. J Clin Oncol, 2007; 25:4536-4541.

151.Clark JI, Mehrabi J, Sosman JA, Logan RF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB: Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: A cytokine working group study. J Immunotherapy 2007; 30; 839-846.

152.Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark J, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood J, Panka D, Crosby NA, O’Boyle K, LaFleur B, Ernstoff M: Three phase II Cytokine Working Group (CWG) trials of gp100 (210M)-peptide plus high-dose Interleukin-2 in HLA-A2+ advanced melanoma patients. J Clin Oncol, 2008; 26; 2292-2298.

153.Atkins M, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G, Curti B, Margolin K: Temozolomide, thalidomide and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II trial of the Cytokine Working Group. Cancer 2008; 113; 2139-2145. PMID. 18792064

154.Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, Archer L, Atkins JN, Czaykowski P, Dutcher J, Small EJ: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26; 5422-5428.

155.Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management of multi-targeted kinase inhibitor-associated hand-foot skin reaction. Oncologist, 2008; 13; 1001-1011.

156.Dutcher JP, deSouza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G: Effect of Temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Onc 2009; 26; 202-209.

157.Figlin RA, deSouza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G: Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon- α. Cancer 2009; 115 (16); 3651-3660.

158.Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol, 2009; 27; 1-8.

159.Gordon M, Hussey M, Nagle R, Lara Jr, P, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan C-X, Crawford D: Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol, 2009; Dec 1; 27 (34); 5788-5793.

160.Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, on behalf of the ARCCS study investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, Epub Jan 15, 2010; Cancer 2010; 116:1272-1280. PMID: 20082451.

161.Dutcher JP, Morris EL, Gaynor B, Paietta E, Wiernik PH: A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. Medical Oncology, 2010; 27:728-735. Epub 2009, August 21. PMID:19697165.

162.Rini BI, Halabi S, Roseberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher JP, Small EJ: Phase III trial of bevacizumab and interferon – alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010; 28; 2137-2143. PMID: 20368558.

163.Malouf GG, Camparo P, Oudard S,Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Bompas E, Guillot A, Couturier J, Molinie V, Escudier B: Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma : A Report from the Juvenile RCC Network. Ann Oncol, 2010; 21 (9):1834-1838. Epub ahead of print, Feb 12 2010. PMID 20154303

164.Bukowski R, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller Jr, WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C-H, Cupit L, Figlin RA., for the AARCS trial: Safety and efficacy of sorafenib in elderly patients treated in the North American Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded access program. Oncology 2010; 78; 340-347.

165.Wiernik PH, Dutcher JP, Yao X-P, Venkatraj U, Falkson CI, Rowe JM, Cassileth. Phase II study of interleukin-4 in indolent B-cell non-Hodgkins lymphoma and B-cell chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E5Y92). J Immunotherapy, 2010; 33(9); 1006-1009.

166.Lee SH, Baig M, Rusciano V, Dutcher JP. Novel management of pruritis in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunotherapy. 2010; 33(9); 1010-1013.

167.Dutcher JP, Tannir N, Bellmunt J, Escudier B: Experience with sorafenib in the elderly patient. Med Oncol 2010; 27 (4) : 1359-1370. Epub 2009, Dec 31

168.Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell carcinoma treated with chemotherapy, Med Oncol, 2011 28(4):1530-1533. Epub 2010 Aug 18

169.Malouf GG, Caparo P, Molinie V, Dedet G,Oudard S, Schleiermacher G, Theodore C, Dutcher J, Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturieer J, Escudier B. TFE3 and TFEB renal cell carcinomas: Clinical features, biological behaviour and prognostic factors. J Urology, 2011; 185; 24-29. Epub Nov 12, 2010. PMID 21074195

170. Moroto JP, Hudes G, Dutcher JP, Logan TF, White C, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A: Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol, 2011; 29:1750-1756.

170.Manola J,Bacik J, Elson P,Royston P,Mazumdar M, Motzer R, Negrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng D, Choueiri TK, Bukowski R: Prognostic factors for survival in patients with metastatic renal cell carcinoma: Results from the International Kidney Cancer Working Group. Clin Cancer Res 2011; 17 (16): 5443-5450; epub 2011 Aug 9;

171.Haas NB, Lin C, Manola J, Pins M, Liu G,McDermott D, Nanus D, Heath E, Wilding G, Dutcher, J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol, 2012; 29 (2): 761-767. Epub 2011, Feb 6;

172.Dutcher JP, Mourad W, Ennis RD: Integrating innovative therapeutic strategies into the management of renal cell carcinoma. Oncology June 2012; 526-534.

173.Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson T: Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis. In Press, Br J Cancer, 2013

174.Rini BI, Garrett M, Poland B, Dutcher J, Rixe O, Wilding G, Stadler WM, Pithavala Y, Kim S, Tarazi J, Motzer R. Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacology 53 (5):491-504, 2013

175.Dandamudi UB, Ghebremichael M, Sosman J, Clark J, McDermott D, Atkins M, Dutcher JP, Urba W, Regan M, Puzanov I, Crocenzi T, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS: A phase II study of Bevacizumab and high dose Interleukin-2 in patients with metastatic renal cell carcinoma: A Cytokine Working Group (CWG) Study J Immunotherapy,

36:490-495, 2013.

176.Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Steward JA, Chachoua A, Schuchter LM: Report of a phase I trial of Interleukin-1 Alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1 based studies of hematopoietic reconstitution. In press, J Interferon and Cytokine Research 34:376-384, 2014. EPUB 2014 Jan 15 PMC 4015471

177.Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin Jr WG, Dutcher JP: A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014, Aug 25 (8): 1603-1608. Epub May 2014 DOI:10.1093. 00:1-6.

178.Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB: High dose Interleukin-2 (Aldesleukin) – expert consensus on best management practices – 2014. J ImmunoTherapy of Cancer 2014; 2:26

179.McDermott DF, Cheng S-C, Signoretti S, Margolin KA, Clark J, Sosman J, Dutcher J, Logan T, Curti B, Ernstoff M, Appleman L, Wong M, Kushalani N, Oleksowicz L, Vaishampayan U, Mier J, Panka D, Bhatt RS, Bailey A, Leibovich B, Kwon E, Kabbinavar F, Belldegrun A, Figlin R, Pantuck A, Regan M, Atkins MB: The high dose Aldesleukin (HD IL-2) “Select” trial: A trial designed to prospectively validate predictive models of response to HD IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21(3):561-568.

181.Flaherty K, Manola J, Pins M, McDermott DF, Atkins MB, Dutcher JP, George DJ, Margolin KA, DiPaola RS: ECOG E2804: A randomized phase II study of VEGF, RAF Kinase and mTOR combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma In Press, J Clin Oncol 2015.

182.Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher J, Wilding G. Atrasentan in patients with advanced renal cell carcinoma: A phase II trial of the Eastern Cooperative Oncology Group. Submitted, 2013.

183.Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood CG, Atkins MB, Dutcher JJ, Hariharan S, DiPaola RS. Effects of sorafenib and sunitinib on cardiac function in a population without overt metastases: Cardiac substudy of a phase III trial of sunitinib or sorafenib or placebo in patients with high risk resected renal cell carcinoma (E2805). In press, Clin Cancer Res 2015.

184.Mowla M, Bojanapally P, Rustine A, Graham S, Dutcher JP. Real practice experience with temsirolimus in metastatic renal cell carcinoma. Manuscript in preparation, 2012.

185.Logan TF, Szczylik C, Tannir N, Benedetto P, Makhson A, McDermott D, Ruff P, Mikulas J, Dutcher JP, Berkenblit A, Galand L, Krygowski M, Hudes G: Effect of nephrectomy status on temsirolimus efficacy in patients with advanced poor-prognosis renal cell cancer. 2012, Submitted Urology

B.Case Reports

1.Dutcher JP, Aisner J, Hogge D, Schiffer CA: Brief Report: Donor reaction to hydroxyethyl starch during granulocytopheresis. Transfusion 1984; 24; 66-67.

2.Dutcher JP and Wiernik PH - Case Report: Long term survival of a patient with multiple myeloma - A Cure? Cancer 1984; 53; 2069-2072.

3.Dutcher JP, Wiernik PH, Gray WC: Tonsillectomy for recurrent throat infections in acute leukemia patients. N Engl J Med 1984; 311; 408. (letter to the editor).

4.Paietta E, Papenhausen P, Ciobanu N, Dutcher JP, Wiernik PH: Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma. Cancer Genetics and Cytogenetics 1986; 21; 355-360.

5.Paietta E, Papenhausen P, Dutcher JP, Wiernik PH: Cytogenetic and phenotypic evolution in a case of acute promyelocytic leukemia. Cancer Genetics and Cytogenetics 1986; 21;181-182. (letter to the editor).

6.Gelman KM, Ben-Ezra JM, Steinschneider M, Keefe DL, Dutcher JP, Factor SM: Lymphoma with primary cardiac manifestations. Am Heart Journal 1986; 111; 808-811.

7.Dutcher JP, Fisher M, Spivack M, Wiernik PH: Porphyria cutanea tarda in a patient with acute leukemia. Am J Hematol 1986; 23; 69-75.

8.Dutcher JP, Wiernik PH: Acute leukemia in a patient cured of diffuse histiocytic lymphoma. Cancer Res and Clinical Oncol 1986; 112; 67-70.

9.Lauer SA, Fischer J, Jones J, Gartner S, Dutcher J, Hoxie J: Orbital involvement in systemic adult T-cell leukemia/lymphoma (ATLL) associated with human T-cell leukemia virus-I (HTLV-I) infection. Ophthalmology 1988; 95; 110-115.

10.Catanese J, Dutcher JP, Dorfman HD, Andres DF, Wiernik PH: Mediastinal osteosarcoma with extension to lungs in a patient treated for Hodgkin's disease. Cancer 1988; 62; 2252-2257.

11.Simon KE, Dutcher JP, Runowicz CD, Wiernik PH: Adenocarcinoma arising in vulvar breast tissue. Cancer 1988; 62; 2234-2238.

12.Feinfeld DA, D'Agati V, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH: Interstitial nephritis in a patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine activated killer cells. Am J Nephrology 1992; 11; 489-492.

13.Gucalp R, Motyl M, Carlisle P, Dutcher J, Fuks J, Wiernik PH: Clostridium cadaveris bacteremia in the immunocompromised host. Med Ped Oncol 1993; 21; 70-72.

14.Sparano JA, Brandt LJ, Dutcher JP, DuBois JS, Atkins MB: Symptomatic exacerbation of Crohns disease after treatment with high-dose interleukin-2. Ann Intern Med 1993; 118; 617-618.

15.Dutcher JP, Benchabbat A, Jones JG, Wiernik PH: Unique dermatological complication of rhM-CSF treatment. Leukemia and Lymphoma 1994; 15; 347-349.

16. Merer DM, Dutcher JP, Mercando A, Brodman R, Suhrland MJ, Bhandari A, Zimmerman D, Mitchell MS, Wiernik PH: Clinical findings and successful resection of melanoma metastatic to the right atrium. Cancer Investigation 1994; 12(4); 409-413.

17.Wiernik PH, Dutcher JP, Leaf AN, Liao Z, Paietta E, Rosenstreich DL: Objective response of multiple myeloma to cyclosporin A. Leukemia and Lymphoma 1994; 6; 167-170.

18.Wiernik PH, Sklarin NT, Dutcher JP, Sparano JA, Greenwald ES: Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer. Medical Oncology 1994; 11; 121-125.

19.Einzig AI, Dutcher JP, Wiernik PH: Life-threatening hyperleukocytosis and pulmonary compromise after priming with rh-GMCSF in a patient with AML. J Clin Oncol 1995; 13; 304. (letter)

20.Gucalp R., Carlisle P, Gialanella P, Mitsudo S., McKitrick J., Dutcher JP: Paecilomyces sinusitis in an immunocompromised adult patient: Case report and review. Clinical Infectious Diseases 1996; 23; 391-393.

21.Makower D, Venkatraj U, Dutcher JP, Wiernik PH: Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leukemia and Lymphoma 1996; 23; 617-619.

22.Wiernik PH, DeBellis R, Muxi P, Dutcher JP: Extramedullary acute promyelocytic leukemia. Cancer 1996; 78; 2510-2514.

23.Malik UR, Oleksowicz L, Dutcher JP, Ratech H, Borowitz MJ, Wiernik PH: Atypical clonal T-cell proliferation in infectious mononucleosis. Medical Oncology 1996; 13; 207-213.

24.Suh J-G, Oleksowicz L, Dutcher JP: Leukocytoclastic vasculitis associated with nizatidine therapy. Am J Med 1997; 102; 216-217.

25.Malik U, Dutcher JP, Oleksowicz L: Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: A case report and literature review. Cancer 1998; 82; 1764-1768.

26.Bhagwati N, Seno R, Dutcher JP, Oleksowicz L: Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia. Hematopathology and Molecular Hematology 1998; 11; 101-108.

27.Deshpande H, Dutcher JP, Novik Y, Oleksowicz L: Successful treatment of a patient on adrenal steroid replacement therapy with high-dose interleukin-2 for metastatic renal cell carcinoma. (Letter) The Cancer Journal from Scientific American 1999; 5(Jan-Feb); 52-53.

28.Blokh I, Oiseth SJ, Fuks J, Jain D, Eapen S, Koulova L, Alexandrescu D, Li YY, Dutcher JP, Wiernik PH: Metastatic choriocarcinoma in a middle-aged man presenting as a right thigh mass with venous thrombosis: A case report. Medical Oncology 2003; 20(2); 189-194.

29.O’Boyle KP, Murigeppa A, Jain D, Dauber L, Dutcher JP, Wiernik PH: Probable veno-occlusive disease after treatment with Gemtuzumab Ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis. Medical Oncology 2003; 20; 379-383.

30.Alexandrescu DT, Dutcher JP, O’Boyle K, Albulak M, Oiseth S, Wiernik PH: Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin’s lymphoma. Leukemia/ Lymphoma 2004; 45 (11); 2321-2325.

31.Koulova L, Alexandrrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH: Rituximab in the treatment of refractory idiopathic throbocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): A report of three cases. Am J Hematology, 2005; 78; 49-54.

32.Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH: Strokes after intravenous gamma globulin: Thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol 2005; 78(3); 216-220.

33.Alexandrescu DT, Maddukauri P, Wiernik PH, Dutcher JP: Thrombotic thrombocytopenic purpura/Hemolytic uremic syndrome (TTP/HUS) associated with high-dose interleukin-2 for the treatment of metastatic melanoma. J Immunotherapy 2005; 28(2); 144-147.

34.Alexandrescu DT, Dutcher JP: Capecitabine-induced pancolitis, Internatl J Colorectal Dis, 2005; Jul 20. (epub)

35.Dasanu CA, Alexandrescu DT, Dutcher JP: Case Report: Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. Southern Medical Journal 2007; 100; 328-330. Erratum in May 2007; 100;485, with correction of authorship.

36.Wiernik PH, Baig MA, Lee SH, Dutcher JP, Paietta E, Racevskis J: Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. Clinical Advances in Hematology and Oncology 2011; 9:242-248.

37.Nagubandi R, Wang J, Dutcher J, Rao S,: A Classic Case of Unicentric Mixed Type Castleman’s disease. 2013, In Press 2013 J Clin Oncol; Diagnosis in Cancer ; Epub ahead of print October 14, 2013 as 10.1200/JCO.2012.45.9941

38.

Cabot JC, Hussein S, Lee SH, DiNorcia J, Dutcher JP, Chabot JA: Renal cell cancer with metachronous metastasis to the gallbladder: A case report and review of the literature. Manuscript in preparation, 2012.

C.Reviews, Chapters, Editorials and Commentaries

1. Dutcher JP and Wiernik PH: Adult leukemia: How to recognize the early signs. Your Patient & Cancer 1981; 1; 37-40.

2. Dutcher JP and Wiernik PH: Adult leukemia: Treatment of choice, maintenance therapy, supportive care. Your Patient and Cancer 1981; 1; 32-46.

3. Schiffer CA, Aisner J, Dutcher JP, Daly PA, Wiernik PH: A clinical program of platelet cryopreservation. WR Vogler, Ed; In Cytapheresis and Plasma Exchange: Clinical Indications; Alan R. Liss, Inc; Phila; 1982; pp. 165-80.

4. Dutcher JP, Schiffer CA: Platelet and granulocyte transfusion therapy. PH Wiernik (ed); In Supportive Care of the Cancer Patient; Futura; Mt. Kisco, NY; 1983; pp. l09-l44.

5. Schnaper N, Legg-McNamara C, Dutcher JP, Kellner TK: Emotional support of the patient and his survivors. PH Wiernik (ed); In Supportive Care of the Cancer Patient; Futura; Mt. Kisco, N.Y.; 1983; pp. l-l6.

6. Dutcher JP and Wiernik PH: The Leukemias. In Spittell JA (ed); Clinical Medicine, Vol. 5, Chap. 16; 1983; pp. 1-25.

7. Dutcher JP and Wiernik PH: Acute Non-Lymphocytic Leukemia. American Society of Hematology Educational microfishe and manual - 1983.

8. Wiernik PH, Dutcher JP: Some new drugs in acute nonlymphocytic leukemia (ANLL). Proc 13th Int Cong Chemother 1983; 237; 52-55.

9. Dutcher JP and Wiernik PH: The Leukemias. J Spivak (ed); . In Fundamentals of Clinical Hematology, Second Ed